{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:29:22Z","timestamp":1777645762500,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.cgh.2022.07.005","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T22:35:24Z","timestamp":1658183724000},"page":"1513-1522.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9119-4610","authenticated-orcid":false,"given":"Hannah S.J.","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grishma","family":"Hirode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tung-Hung","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wai-Kay","family":"Seto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stijn","family":"Van Hees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Papatheodoridi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabela","family":"Lens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace L.H.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia M.","family":"Brakenhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Nan","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milan J.","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry L.Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Forns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George V.","family":"Papatheodoridis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Vanwolleghem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man-Fung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Chun","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Cornberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina E.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Juei","family":"Jeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2398-8392","authenticated-orcid":false,"given":"Harry L.A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2022.07.005_bib2","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients\u2013FINITE study","volume":"67","author":"Berg","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2022.07.005_bib3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.07.005_bib4","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3851\/IMP3256","article-title":"Daring-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B","volume":"23","author":"Papatheodoridis","year":"2018","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cgh.2022.07.005_bib5","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/hep.26549","article-title":"Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients","volume":"58","author":"Jeng","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.07.005_bib6","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.cmi.2017.12.013","article-title":"Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients","volume":"24","author":"Chen","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cgh.2022.07.005_bib7","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/apt.14560","article-title":"Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes","volume":"47","author":"Van Hees","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.07.005_bib8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.07.005_bib9","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/gutjnl-2014-307237","article-title":"Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study","volume":"64","author":"Seto","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2022.07.005_bib10","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1136\/gutjnl-2019-318981","article-title":"Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: Results from a randomised controlled trial (Toronto STOP study)","volume":"68","author":"Liem","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2022.07.005_bib11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/apt.15053","article-title":"Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir","volume":"49","author":"Kuo","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2022.07.005_bib12","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/infdis\/jix690","article-title":"Distinct relapse rates and risk predictors after discontinuing tenofovir and entecavir therapy","volume":"217","author":"Su","year":"2018","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cgh.2022.07.005_bib13","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/infdis\/jiy350","article-title":"Contrasting timing of virological relapse after discontinuation of tenofovir or entecavir in hepatitis B e antigen-negative patients","volume":"22","author":"H\u00f6ner zu Siederdissen","year":"2018","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cgh.2022.07.005_bib14","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.cgh.2016.07.002","article-title":"Clinical relapse after cessation of tenofovir therapy in hepatitis B e antigen\u2013negative patients","volume":"14","author":"Jeng","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.07.005_bib15","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2022.07.005_bib16","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1016\/j.cgh.2020.04.048","article-title":"Associations of HBV genotype B vs C infection with relapse after cessation of entecavir or tenofovir therapy","volume":"18","author":"Chiu","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2022.07.005_bib17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s12072-019-09998-5","article-title":"Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B","volume":"14","author":"Mak","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cgh.2022.07.005_bib18","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/hep.28438","article-title":"Discontinuation of oral antivirals in chronic hepatitis B: a systematic review","volume":"63","author":"Papatheodoridis","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2022.07.005_bib19","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/infdis\/jiw412","article-title":"Viral and host responses after stopping long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic Hepatitis B","volume":"214","author":"H\u00f6ner Zu Siederdissen","year":"2016","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cgh.2022.07.005_bib20","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/gutjnl-2016-312653","article-title":"Induction of IFN-\u03bb3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection","volume":"67","author":"Murata","year":"2018","journal-title":"Gut"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356522006723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356522006723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:43:47Z","timestamp":1761543827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356522006723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1542356522006723"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2022.07.005","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2022.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the AGA Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}